GlycoMimetics Liabilities 2024

GlycoMimetics Aktienanalyse

What does GlycoMimetics do?

GlycoMimetics Inc is a biopharmaceutical company specializing in the discovery and development of new drugs for the treatment of cancer and inflammatory diseases. The company was founded in 2003 and is headquartered in Rockville, Maryland. GlycoMimetics' business model is based on the application of glycomimetics, a class of molecules that mimic glycoproteins found in cells. These molecules act in various ways, offering unique therapeutic possibilities in the treatment of cancer and inflammatory diseases. The company conducts research and development in various areas, including the discovery of new drugs, preclinical and clinical drug development, and the evaluation of drug candidates for their transition into clinical trials. One of GlycoMimetics' most important developments is a drug called Rivipansel. This medication is used for the treatment of acute pain and crises in patients with sickle cell anemia. A Phase III clinical trial for Rivipansel was successfully completed in 2019. Another significant aspect of GlycoMimetics' business model is its collaboration with other companies specializing in similar technologies. For example, the company has partnered with Apollomics to advance the development of GMI-1271, a drug candidate for the treatment of Acute Myeloid Leukemia (AML). GlycoMimetics has various research and development areas that are crucial for the development and testing of drug candidates in clinical trials. The company has expertise in chemistry and biological sciences and employs researchers and scientists with diverse backgrounds. One of GlycoMimetics' divisions is medicinal chemistry, which focuses on the synthesis of natural compounds and chemical compounds to identify and develop new drug candidates. The company also has expertise in protein diagnostics, which are used to validate target molecules and assess the effectiveness of drug candidates. Another important division of GlycoMimetics is the field of immunology. Here, the company explores the role of glycoproteins in immune reactions and develops drugs for the treatment of autoimmune diseases. Overall, GlycoMimetics has strong research and development capabilities, enabling the company to develop new drug candidates, conduct clinical trials, and achieve successful growth. With its innovative developments and products, GlycoMimetics contributes to the improvement of the health of many patients and is an important player in the biopharmaceutical industry. GlycoMimetics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing GlycoMimetics's Liabilities

GlycoMimetics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating GlycoMimetics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing GlycoMimetics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

GlycoMimetics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in GlycoMimetics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about GlycoMimetics stock

What is the level of liabilities of GlycoMimetics this year?

GlycoMimetics has a debt balance of 6.9 M USD this year.

What were the liabilities of GlycoMimetics compared to the previous year?

The liabilities of GlycoMimetics have increased by -22.45% dropped compared to the previous year.

What are the consequences of high debt for investors of GlycoMimetics?

High liabilities can pose a risk for investors of GlycoMimetics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in GlycoMimetics?

Low liabilities mean that GlycoMimetics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of GlycoMimetics affect the company?

An increase in liabilities of GlycoMimetics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of GlycoMimetics affect the company?

A decrease in the liabilities of GlycoMimetics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of GlycoMimetics?

Some factors that can influence the liabilities of GlycoMimetics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of GlycoMimetics so important for investors?

The liabilities of GlycoMimetics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can GlycoMimetics take to modify the liabilities?

To change its liabilities, GlycoMimetics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does GlycoMimetics pay?

Over the past 12 months, GlycoMimetics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, GlycoMimetics is expected to pay a dividend of 0 USD.

What is the dividend yield of GlycoMimetics?

The current dividend yield of GlycoMimetics is .

When does GlycoMimetics pay dividends?

GlycoMimetics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of GlycoMimetics?

GlycoMimetics paid dividends every year for the past 0 years.

What is the dividend of GlycoMimetics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is GlycoMimetics located?

GlycoMimetics is assigned to the 'Health' sector.

Wann musste ich die Aktien von GlycoMimetics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of GlycoMimetics from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did GlycoMimetics pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of GlycoMimetics in the year 2023?

In the year 2023, GlycoMimetics distributed 0 USD as dividends.

In which currency does GlycoMimetics pay out the dividend?

The dividends of GlycoMimetics are distributed in USD.